A large body of validation work of MTHFD2 as an anticancer target has been ongoing in recent years, demonstrating that MTHFD2 RNA interference depletion or inhibition can kill cancer cells of diverse origin such as acute myeloid leukaemia (AML)16,17, breast cancer18 and colorectal cancer19. Here, MTHFD2 is linked to acute myeloid leukemia.